Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis

Inclusion Criteria: * Diagnosis of cystic fibrosis confirmed * Age ≥18 years * 30% \<FEV1 \<70% predicted * Presence of bronchial congestion reported by the patient or the investigator Exclusion Criteria: * Uncontrolled asthma * Pneumothorax \<6 weeks * Recent severe hemoptysis \<6 weeks * Patient registered on the transplant list * Exacerbation within 4 weeks (3 months if hospitalization) before screening * Cardiovascular disorders, electrocardiogram (ECG) parameters or clinically significant respiratory (non-cystic fibrosis) conditions * Patients unable to perform measurements of ROF, spirometry, plethysmography. * Any contraindication to manual or instrumental physiotherapy. * Pregnancy, breastfeeding. * Patient under tutorship or curatorship * No affiliation to the French social security * Patient using Simeox at home * Patient under Trikafta for less than 6 weeks. * Patient using Simeox more than twice a week during physiotherapy sessions, not wanting a washout period of 7 days before inclusion